Cargando…

Encephalopathy Due to COVID-19 With Great Response to Glucocorticoids

Minor neurological symptoms such as anosmia are relatively common manifestations of coronavirus disease 2019 (COVID-19). However, severe affection of the central nervous system (CNS) occurs in a minority of cases and its treatment and pathophysiology is not yet well understood. It has been described...

Descripción completa

Detalles Bibliográficos
Autores principales: Pizzato Tondo, Lucca, Beck Paglioli Neto, Eduardo, Arpini, Soel, Passos, Giordani, Becker, Jefferson
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8501896/
https://www.ncbi.nlm.nih.gov/pubmed/34660051
http://dx.doi.org/10.7759/cureus.17845
_version_ 1784580768556646400
author Pizzato Tondo, Lucca
Beck Paglioli Neto, Eduardo
Arpini, Soel
Passos, Giordani
Becker, Jefferson
author_facet Pizzato Tondo, Lucca
Beck Paglioli Neto, Eduardo
Arpini, Soel
Passos, Giordani
Becker, Jefferson
author_sort Pizzato Tondo, Lucca
collection PubMed
description Minor neurological symptoms such as anosmia are relatively common manifestations of coronavirus disease 2019 (COVID-19). However, severe affection of the central nervous system (CNS) occurs in a minority of cases and its treatment and pathophysiology is not yet well understood. It has been described that encephalitis due to COVID-19 may be caused by the proinflammatory state due to the cytokine storm or direct invasion of the virus in the CNS. Here we present a case of a 66-year-old man with bipolar disorder and moderate respiratory COVID-19 symptoms who presented to the emergency department with a decreased level of consciousness. Brain computerized tomography (CT) showed no acute pathology. A thorough investigation of other possible causes of CNS affection was negative. The patient was treated with pulse therapy with methylprednisolone and presented a significant improvement of his neurological condition, being discharged with a complete neurological recovery five days after the start of the treatment. This case illustrates the importance of a high index of suspicion in diagnosing severe CNS impairment in mild respiratory COVID-19 cases. Also, this case corroborates with previous reports of glucocorticoid response in CNS impairment associated with COVID-19, although more robust studies are required to confirm this relation. 
format Online
Article
Text
id pubmed-8501896
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-85018962021-10-14 Encephalopathy Due to COVID-19 With Great Response to Glucocorticoids Pizzato Tondo, Lucca Beck Paglioli Neto, Eduardo Arpini, Soel Passos, Giordani Becker, Jefferson Cureus Neurology Minor neurological symptoms such as anosmia are relatively common manifestations of coronavirus disease 2019 (COVID-19). However, severe affection of the central nervous system (CNS) occurs in a minority of cases and its treatment and pathophysiology is not yet well understood. It has been described that encephalitis due to COVID-19 may be caused by the proinflammatory state due to the cytokine storm or direct invasion of the virus in the CNS. Here we present a case of a 66-year-old man with bipolar disorder and moderate respiratory COVID-19 symptoms who presented to the emergency department with a decreased level of consciousness. Brain computerized tomography (CT) showed no acute pathology. A thorough investigation of other possible causes of CNS affection was negative. The patient was treated with pulse therapy with methylprednisolone and presented a significant improvement of his neurological condition, being discharged with a complete neurological recovery five days after the start of the treatment. This case illustrates the importance of a high index of suspicion in diagnosing severe CNS impairment in mild respiratory COVID-19 cases. Also, this case corroborates with previous reports of glucocorticoid response in CNS impairment associated with COVID-19, although more robust studies are required to confirm this relation.  Cureus 2021-09-09 /pmc/articles/PMC8501896/ /pubmed/34660051 http://dx.doi.org/10.7759/cureus.17845 Text en Copyright © 2021, Pizzato Tondo et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Neurology
Pizzato Tondo, Lucca
Beck Paglioli Neto, Eduardo
Arpini, Soel
Passos, Giordani
Becker, Jefferson
Encephalopathy Due to COVID-19 With Great Response to Glucocorticoids
title Encephalopathy Due to COVID-19 With Great Response to Glucocorticoids
title_full Encephalopathy Due to COVID-19 With Great Response to Glucocorticoids
title_fullStr Encephalopathy Due to COVID-19 With Great Response to Glucocorticoids
title_full_unstemmed Encephalopathy Due to COVID-19 With Great Response to Glucocorticoids
title_short Encephalopathy Due to COVID-19 With Great Response to Glucocorticoids
title_sort encephalopathy due to covid-19 with great response to glucocorticoids
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8501896/
https://www.ncbi.nlm.nih.gov/pubmed/34660051
http://dx.doi.org/10.7759/cureus.17845
work_keys_str_mv AT pizzatotondolucca encephalopathyduetocovid19withgreatresponsetoglucocorticoids
AT beckpagliolinetoeduardo encephalopathyduetocovid19withgreatresponsetoglucocorticoids
AT arpinisoel encephalopathyduetocovid19withgreatresponsetoglucocorticoids
AT passosgiordani encephalopathyduetocovid19withgreatresponsetoglucocorticoids
AT beckerjefferson encephalopathyduetocovid19withgreatresponsetoglucocorticoids